Core Insights - In the third quarter of 2025, Innotech (688253.SH) reported that a total of 9 institutional investors disclosed holdings in its A-shares, amounting to 62.69 million shares, which represents 45.77% of Innotech's total share capital [1] - The proportion of shares held by institutional investors increased by 1.51 percentage points compared to the previous quarter [1] Group 1: Institutional Holdings - A total of 9 institutional investors hold shares in Innotech, with a combined holding of 62.69 million shares [1] - The institutional investors include various management centers and investment firms, indicating a diverse range of institutional interest [1] - The increase in institutional holdings suggests growing confidence in Innotech's performance [1] Group 2: Public Fund Holdings - One public fund, the Medical Device ETF, increased its holdings by 0.20% compared to the previous period [2] - A total of 78 public funds did not disclose their holdings in this period, including notable funds such as CITIC Securities Excellence Growth A and Southern Value One-Year Holding Mixed A [2] - The lack of disclosure from a significant number of public funds may indicate a cautious approach towards investment in Innotech [2]

Core Viewpoint - Jianerkang (603205.SH) reported a slight decrease in institutional investor holdings in its third-quarter report for 2025, indicating a potential shift in investor sentiment within the medical device sector [1] Group 1: Institutional Holdings - As of October 30, 2025, four institutional investors disclosed holdings in Jianerkang A-shares, totaling 13.1551 million shares, which represents 8.43% of the total share capital [1] - The combined institutional holding ratio decreased by 0.12 percentage points compared to the previous quarter [1] Group 2: Public Fund Holdings - One public fund, the Medical Device ETF, increased its holdings during this period, with an increase ratio of 0.12% [1] - A total of 138 public funds did not disclose their holdings this quarter, including several notable funds such as the China Securities Medical Device ETF and the China Securities Healthcare Equipment and Services ETF [1]

Core Viewpoint - Capstone Bio (300639.SZ) reported its Q3 2025 results, highlighting a significant institutional investment presence with 43.69% of total shares held by six institutional investors as of October 28, 2025 [1] Institutional Holdings - A total of 6 institutional investors disclosed holdings in Capstone Bio, amounting to 282 million shares, which represents 43.69% of the company's total equity [1] - The institutional holding percentage increased by 0.13 percentage points compared to the previous quarter [1] Public Fund Holdings - One public fund, the Medical Device ETF, increased its holdings during this period, with an increase percentage of 0.21% [1] - A total of 46 public funds did not disclose their holdings in this quarter, including notable funds such as Guojin Quantitative Multi-Factor A, E Fund CSI Wande Biotechnology Index (LOF) A, and others [1]

Core Viewpoint - Meikang Bio (300439.SZ) reported its Q3 2025 results, highlighting a slight increase in institutional ownership and changes in public fund holdings [1] Institutional Investors - As of October 28, 2025, two institutional investors disclosed holdings in Meikang Bio A-shares, totaling 41.41 million shares, which represents 10.78% of the total share capital [1] - The institutional ownership increased by 0.03 percentage points compared to the previous quarter [1] Public Funds - One public fund, the Medical Device ETF, increased its holdings, contributing to a rise of 0.21% in ownership [1] - A total of 33 public funds did not disclose their holdings in this period, including notable funds such as E Fund CSI Wind Bio-Tech Index (LOF) A and others [1]

Group 1 - Zhenghai Biological (300653.SZ) released its Q3 2025 report on October 25, 2025, indicating that as of October 24, 2025, six institutional investors disclosed holdings in Zhenghai Biological A-shares, totaling 21.9322 million shares, which accounts for 12.18% of the total share capital [1] - The institutional investors include Longwood Biotechnologies Inc., Jiaxing Zhenghai Venture Capital Partnership (Limited Partnership), Industrial and Commercial Bank of China - Dongfanghong New Power Flexible Allocation Mixed Securities Investment Fund, and others, with a total institutional holding ratio increasing by 0.33 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, four public funds increased their holdings compared to the previous period, including Dongfanghong New Power Mixed A, Medical Device ETF, and others, with an increase in holding ratio of 0.94% [2] - A total of 43 public funds did not disclose their holdings in this period compared to the previous quarter, including Taiping Fenghe One-Year Open-Ended Bond Initiated Fund, Dongfanghong Zhihua Three-Year Holding Mixed A, and others [2]

Core Viewpoint - The report highlights the performance and management of the Yongying CSI All-Share Medical Device ETF Fund for the second quarter of 2025, emphasizing its investment strategy, financial metrics, and market outlook for the medical device industry. Fund Overview - The fund aims to closely track the performance of the CSI All-Share Medical Device Index, with a total fund share of 470,599,906.92 as of the report date [1]. - The fund operates as an open-ended ETF and was established on November 22, 2021 [1]. Financial Performance - The net asset value (NAV) for the Yongying CSI All-Share Medical Device ETF Initiating Link A was 0.6086 RMB, with a net value growth rate of -0.26% during the reporting period [5]. - For the same period, the performance benchmark yielded a return of -0.89% [5]. - The NAV for the Yongying CSI All-Share Medical Device ETF Initiating Link C was 0.6043 RMB, with a net value growth rate of -0.31% [5]. Investment Strategy - The fund primarily employs an index investment strategy, investing in the target ETF to achieve close tracking of the benchmark index [5]. - The fund's investment strategy includes stock investment, bond investment, and asset-backed securities investment, among others [1]. Market Outlook - The medical device sector is expected to see significant performance improvements in the third quarter, driven by high growth rates in bidding data since November 2024 and supportive government policies for high-end medical devices [4]. - The integration of AI technologies in medical devices is anticipated to enhance innovation and market competitiveness [4]. Management Report - The fund management adheres to strict compliance with investment regulations and maintains a disciplined investment research and decision-making process [3]. - The management emphasizes fair trading practices and has not encountered any significant violations of fair trading during the reporting period [4]. Fund Share Changes - The total shares for Yongying CSI All-Share Medical Device ETF Initiating Link A increased from 131,880,539.89 to 133,505,066.16 during the reporting period [7]. - For Initiating Link C, shares rose from 328,466,280.74 to 337,094,840.76 [7]. Other Important Information - There were no single investors holding more than 20% of the fund shares during the reporting period [7].